Effects of fish oil supplements in NIDDM subjects. Controlled study.
The aim of this study was to evaluate the effects of a fish oil preparation (MaxEPA) on hemostatic function and fasting lipid and glucose levels in non-insulin-dependent diabetic (NIDDM) subjects. Eighty NIDDM outpatients aged 55.9 yr (mean SD 11.5 yr) participated in a prospective double-blind placebo-controlled study of MaxEPA capsules (10 g/day) or olive oil (control) treatment over 6 wk. Patients received either MaxEPA or olive oil in addition to preexisting therapy. Metabolic and hemostatic variables were measured before treatment and after 3 and 6 wk. Platelet membrane eicosapentaenoic acid (EPA) content increased in the treatment group (P less than 0.001). MaxEPA supplementation was associated with a significant fall in total triglycerides (P less than 0.001) but did not affect total cholesterol (P = 0.7) compared with control treatment. Fasting plasma glucose increased after 3 wk (P = 0.01) but not after 6 wk (P = 0.17) treatment with MaxEPA. Spontaneous platelet aggregation in whole blood fell in the MaxEPA group (P less than 0.02) after 6 wk, but there were no changes in agonist-induced platelet aggregation, thromboxane generation in platelet-rich plasma, or plasma beta-thromboglobulin and platelet factor IV levels. An increase in clotting factor VII (P = 0.02), without changes in fibrinogen or factor X levels, occurred in the MaxEPA group. Similar reductions in blood pressure were observed in both groups. Dietary supplementation with MaxEPA capsules (10 g/day) in NIDDM subjects is associated with improvement in hypertriglyceridemia but with deleterious effects in factor VII and blood glucose levels. Most indices of platelet function are unaffected by this therapy.
Academic Unit of Diabetes and Endocrinology, University College, Hampstead, London, United Kingdom.
T J
TJ
Hendra
M E
ME
Britton
D R
DR
Roper
D
D
Wagaine-Twabwe
J Y
JY
Jeremy
P
P
Dandona
A P
AP
Haines
J S
JS
Yudkin
D001786:Blood Glucose / Q000032:analysis; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications; D003925:Diabetic Angiopathies / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D003927:Diet, Diabetic; D004281:Docosahexaenoic Acids; D004338:Drug Combinations; D015118:Eicosapentaenoic Acid; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D005395:Fish Oils / Q000008:administration & dosage / Q000494:pharmacology*; D005527:Food, Fortified; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D013929:Thromboxane B2 / Q000097:blood; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D004338:Drug Combinations; D015525:Fatty Acids, Omega-3; D005395:Fish Oils; D008055:Lipids; C045153:Maxepa; D014280:Triglycerides; D004281:Docosahexaenoic Acids; D013929:Thromboxane B2; D002784:Cholesterol; D015118:Eicosapentaenoic Acid